Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP8 | P40818 | 12/20 | 0.40 |
| ▸ | USP7 | Q93009 | 4/20 | 0.40 |
| ▸ | USP47 | Q96K76 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 3/20 | 0.37 |
| ▸ | CNR2 | P34972 | 3/20 | 0.37 |
| ▸ | CHUK | O15111 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10050471 | 0.82 | USP8 (0.35) | USP8USP7USP47CNR1CNR2 | |
| SCHEMBL10074368 | 0.80 | USP8 (0.57) | USP8USP7USP47 | |
| SCHEMBL29548811 | 0.80 | USP8 (0.57) | USP8USP7USP47 | |
| SCHEMBL24872857 | 0.75 | ALDH1A1 (0.47) | USP8USP7USP47CHUKESR2 | |
| SCHEMBL10075456 | 0.73 | USP8 (0.41) | USP8USP7USP47CNR1CNR2 | |
| SCHEMBL10074369 | 0.73 | USP8 (0.49) | USP8USP7USP47 | |
| SCHEMBL19114663 | 0.72 | USP8 (0.42) | USP8USP7USP47 | |
| SCHEMBL20169151 | 0.71 | SMN1; SMN2 (0.34) | USP8USP7USP47 | |
| SCHEMBL1172933 | 0.71 | MAPT (0.46) | USP8USP7ESR2 | |
| SCHEMBL24872939 | 0.71 | USP8 (0.47) | USP8USP7USP47 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119828-B2 | Material for an organic electroluminescence device and an organic electroluminescence device | IDEMITSU KOSAN CO., LTD. (JP) | 2012-02-21 | — | — | US | disclosed |
| US-20100044686-A1 | MATERIAL FOR AN ORGANIC ELECTROLUMINESCENCE DEVICE AND AN ORGANIC ELECTROLUMINESCENCE DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100044686-A1 | MATERIAL FOR AN ORGANIC ELECTROLUMINESCENCE DEVICE AND AN ORGANIC ELECTROLUMINESCENCE DEVICE | AFF4, KCNH3, HCN4 | USP8 4307/4885USP7 4265/4885USP47 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.